1 July 2015 in International Journal of Pharmaceutics
27 April 2009 in Organic Letters
1 March 2012 in Mini-Reviews in Medicinal Chemistry
Protein kinases have emerged as the most important class of targets in oncology drug discovery because of their major roles in regulating cellular growth and survival. At least, 11 kinase inhibitors have received FDA approval to be used as cancer treatments, and there are continuous efforts to bring more candidates from laboratory benches to the clinic. Although many protein kinase inhibitors directly interact with the ATP binding site, other can alter the kinase conformation to prevent productive ATP binding. Herein we discuss the different mechanisms of action of kinase inhibitors and provide classification of the inhibitors according to their binding sites. Some of these are allosteric inhibitors, ATP competitive inhibitors, protein substrate competitive inhibitors, and covalent bond forming inhibitors. This review provides a broad overview of the relation between mechanism of action and the issues of target selectivity and resistance. Special attention was given to the kinase inhibitors currently in clinical trials.
1 March 2002 in Bioorganic & Medicinal Chemistry
15 June 2010 in International Journal of Pharmaceutics
1 March 2008 in Bioorganic & Medicinal Chemistry Letters